[go: up one dir, main page]

BRPI0409916A - ácidos carboxìlicos substituìdos com fenila - Google Patents

ácidos carboxìlicos substituìdos com fenila

Info

Publication number
BRPI0409916A
BRPI0409916A BRPI0409916-8A BRPI0409916A BRPI0409916A BR PI0409916 A BRPI0409916 A BR PI0409916A BR PI0409916 A BRPI0409916 A BR PI0409916A BR PI0409916 A BRPI0409916 A BR PI0409916A
Authority
BR
Brazil
Prior art keywords
compounds
carboxylic acids
phenyl substituted
ptp
substituted carboxylic
Prior art date
Application number
BRPI0409916-8A
Other languages
English (en)
Inventor
Darren Whitehouse
Shaojing Hu
Haiquan Fang
Michael C Van Zandt
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of BRPI0409916A publication Critical patent/BRPI0409916A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"áCIDOS CARBOXìLICOS SUBSTITUìDOS COM FENILA". São revelados compostos e sais farmaceuticamente aceitáveis de fórmula (A): os quais são úteis no tratamento de distúrbios metabólicos relacionados com resistência à insulina, resistência à leptina, ou hiperglicemia. Compostos da invenção incluem inibidores de Proteína tirosina fosfatases, em particular Proteína tirosina fosfatase-1B (PTP-1B), que são úteis no tratamento de diabetes e outras doenças mediadas pela PTP, tais como câncer, doenças neurodegenerativas e semelhantes. Também são reveladas composições farmacêuticas compreendendo compostos da invenção e métodos para tratar as condições mencionadas acima usando os compostos referidos.
BRPI0409916-8A 2003-04-30 2004-04-30 ácidos carboxìlicos substituìdos com fenila BRPI0409916A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46686803P 2003-04-30 2003-04-30
PCT/US2004/013701 WO2004099170A2 (en) 2003-04-30 2004-04-30 Phenyl substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b

Publications (1)

Publication Number Publication Date
BRPI0409916A true BRPI0409916A (pt) 2006-04-25

Family

ID=33434989

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409916-8A BRPI0409916A (pt) 2003-04-30 2004-04-30 ácidos carboxìlicos substituìdos com fenila

Country Status (13)

Country Link
US (1) US7524878B2 (pt)
EP (1) EP1620422A2 (pt)
JP (1) JP2006525365A (pt)
KR (1) KR20060006954A (pt)
CN (1) CN1812978A (pt)
AU (1) AU2004236248A1 (pt)
BR (1) BRPI0409916A (pt)
CA (1) CA2524235A1 (pt)
EA (1) EA200501713A1 (pt)
MX (1) MXPA05011536A (pt)
NO (1) NO20055129L (pt)
WO (1) WO2004099170A2 (pt)
ZA (1) ZA200509635B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1812979A (zh) 2003-04-30 2006-08-02 药物研发有限责任公司 作为蛋白酪氨酸磷酸酶－1b抑制剂的取代氨基羧酸
BRPI0414487A (pt) 2003-09-17 2006-11-14 Ono Pharmaceutical Co composto de ácido carboxìlico e composições medicinais contendo os mesmos como o ingrediente ativo
ATE515494T1 (de) 2004-05-05 2011-07-15 High Point Pharmaceuticals Llc Neue verbindungen, deren herstellung und verwendung
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR20070083484A (ko) 2004-07-14 2007-08-24 피티씨 테라퓨틱스, 인크. Ｃ형 간염 치료 방법
NZ553329A (en) 2004-07-22 2010-09-30 Ptc Therapeutics Inc Thienopyridines for treating hepatitis C
CA2588776A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Substituted amino carboxylic acids
AU2005307818A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocyclylbiphenyl derivates as protein Tyrosine phosphatase inhibitors
JP2008520692A (ja) * 2004-11-18 2008-06-19 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 複素環置換カルボン酸
DE102004060542A1 (de) 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung
WO2006117657A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Triazolone derivatives as anti-inflammatory agents
WO2007003581A1 (en) 2005-06-30 2007-01-11 Novo Nordisk A/S Phenoxy acetic acids as ppar delta activators
WO2007023882A1 (ja) 2005-08-26 2007-03-01 Shionogi & Co., Ltd. Ｐｐａｒアゴニスト活性を有する誘導体
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
CA2645719A1 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
WO2008033934A1 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryl carboxylic acid derivatives as ptb-1b inhibitors
WO2008033931A1 (en) * 2006-09-13 2008-03-20 The Institutes For Pharmaceutical Discovery, Llc Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
JP2010531358A (ja) 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN101896461A (zh) * 2007-12-13 2010-11-24 安姆根有限公司 γ分泌酶调节剂
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP5752691B2 (ja) 2009-09-29 2015-07-22 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 新規化合物
DE102009046115A1 (de) 2009-10-28 2011-09-08 Bayer Schering Pharma Aktiengesellschaft Substituierte 3-Phenylpropansäuren und ihre Verwendung
JP5814031B2 (ja) * 2010-07-30 2015-11-17 ユー・ディー・シー アイルランド リミテッド 有機電界発光素子、及びジベンゾチオフェン構造又はジベンゾフラン構造を有する有機電界発光素子用材料
CN102382037B (zh) * 2010-09-03 2016-01-20 中国医学科学院药物研究所 苯丙酸类化合物及其制法和药物用途
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
MA34721B1 (fr) 2010-12-07 2013-12-03 Bayer Ip Gmbh Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
WO2012085745A1 (en) 2010-12-23 2012-06-28 Pfizer Inc. Glucagon receptor modulators
EP2673260B1 (en) 2011-02-08 2016-08-17 Pfizer Inc Glucagon receptor modulator
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
JP5647379B2 (ja) 2011-07-22 2014-12-24 ファイザー・インク キノリニルグルカゴン受容体モジュレーター
DE102012208530A1 (de) 2012-05-22 2013-11-28 Bayer Pharma AG Substituierte Piperidinoacetamide und ihre Verwendung
HUE049425T2 (hu) 2013-06-27 2020-09-28 Lg Chemical Ltd GPR120 agonista biaril-származékok
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
JP2017509665A (ja) 2014-04-03 2017-04-06 バイエル ファーマ アクチエンゲゼルシャフト 気道疾患治療のための２，５−ジ置換されたシクロペンタンカルボン酸類
US20170022171A1 (en) 2014-04-03 2017-01-26 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentanecarboxylic acids and their use
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
KR20170098869A (ko) 2014-12-18 2017-08-30 바이엘 파마 악티엔게젤샤프트 치환된 피리딜-시클로알킬-카르복실산, 그를 함유하는 조성물 및 그의 의학적 용도
US10905667B2 (en) 2018-07-24 2021-02-02 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form
WO2023165523A1 (zh) * 2022-03-01 2023-09-07 上海璎黎药业有限公司 一类芳香环取代的甲氧基衍生物及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4243678A (en) * 1977-12-30 1981-01-06 Byk Gulden Lomberg Chemische Fabrik Gmbh Acylhydrocarbylaminoalkanoic acids, compositions and uses
JPS59141540A (ja) * 1983-02-01 1984-08-14 Chisso Corp 三環カルボン酸エステル誘導体
IL122315A (en) * 1992-03-19 2002-03-10 Lilly Co Eli Cyclic peptides and antifungal pharmaceutical compositions containing them
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
DE69821294T2 (de) * 1997-07-25 2004-11-18 Eastman Kodak Co. Lichtempfindliche Silberhalogenidemulsionsschicht mit verstärkter photographischer Empfindlichkeit
DE19907904A1 (de) * 1999-02-24 2000-08-31 Clariant Gmbh Verfahren zur Herstellung von [1,1':4',1"]-Terphenylverbindungen
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US6924292B2 (en) * 2000-03-23 2005-08-02 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
JP4105446B2 (ja) * 2002-02-20 2008-06-25 富士フイルム株式会社 重合性化合物およびそのマトリックスを用いた光学素子

Also Published As

Publication number Publication date
EP1620422A2 (en) 2006-02-01
KR20060006954A (ko) 2006-01-20
US20050004369A1 (en) 2005-01-06
WO2004099170A2 (en) 2004-11-18
NO20055129D0 (no) 2005-11-02
WO2004099170A3 (en) 2005-09-15
US7524878B2 (en) 2009-04-28
ZA200509635B (en) 2007-04-25
JP2006525365A (ja) 2006-11-09
CN1812978A (zh) 2006-08-02
AU2004236248A1 (en) 2004-11-18
NO20055129L (no) 2006-01-23
MXPA05011536A (es) 2006-01-23
CA2524235A1 (en) 2004-11-18
EA200501713A1 (ru) 2006-06-30

Similar Documents

Publication Publication Date Title
BRPI0409916A (pt) ácidos carboxìlicos substituìdos com fenila
BRPI0409924A (pt) ácidos amino carboxìlicos substituìdos
BRPI0409447A (pt) ácidos fenilalcanóicos substituìdos
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
MXPA05011539A (es) Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
BRPI0409914A (pt) ácidos carboxìlicos substituìdos
WO2008033455A3 (en) Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
WO2006055708A3 (en) Heterocycle substituted carboxylic acids for the treatment of diabetes
TW200630327A (en) Substituted phenylalkanoic acids
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR0317458A (pt) EnanciÈmero-s, composto, formulação farmacêutica, método para tratar ou previnir distúrbios de lipìdeos (dislipdemia) associados ou não com resistência à insulina, uso de um composto, método para tratar ou previnir diabetes tipo 2, processo para a preparação de um composto, e, composição farmacêutica
BRPI0413490A (pt) novos compostos
BRPI0416796A (pt) compostos orgánicos
WO2006055625A3 (en) Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
IL199914B (en) Use of protein kinase n beta for the manufacture of a diagnostic agent
BRPI0409109A (pt) novos compostos
BRPI0411484A (pt) composto, formulação farmacêutica, métodos de tratamento ou prevenção de distúrbios de lipìdeo (dislipidemia), e de diabetes do tipo 2, uso de um composto, e, composição farmacêutica
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
TW200630354A (en) Substituted amino carboxylic acids
BR0312722A (pt) Derivados de pirazol heterobicìclico como inibidores de qinase
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
HRP20050103B1 (hr) N-aril supstituirani bifenilkarboksamidi kao inhibitori sekrecije apolipoproteina b
BR112022009881A2 (pt) Inibidores de caspase 6 e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.